If You Invested in Protagonist Ther (PTGX)

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a discovery-through-late-stage development biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, its work centers on a proprietary discovery platform for constrained peptide-based drug candidates, with multiple investigational therapies advancing through Phase 3 clinical development and a broader preclinical pipeline.

Business focus and therapeutic areas

Protagonist describes itself as a biopharmaceutical company spanning discovery to late-stage development. Two novel peptides derived from its proprietary discovery platform are in advanced Phase 3 development: icotrokinra (formerly JNJ-2113) and rusfertide. These programs, together with additional preclinical candidates, position the company in inflammatory and immunological diseases and hematology.

Icotrokinra is characterized by the company as a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin‑23 receptor (IL‑23R). It was jointly discovered by scientists at Protagonist and Johnson & Johnson under an IL‑23R collaboration. Protagonist reports that it was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Icotrokinra is licensed to Janssen Biotech, Inc. (also referenced as J&J Innovative Medicines or Johnson & Johnson), and a New Drug Application (NDA) for icotrokinra has been submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate to severe plaque psoriasis. The company also notes an application to the European Medicines Agency for this indication.

Beyond plaque psoriasis, Protagonist highlights that icotrokinra is being studied in a broad clinical development program, including:

• Phase 3 ICONIC studies in moderate-to-severe plaque psoriasis, including ICONIC‑LEAD and ICONIC‑TOTAL.
• Phase 3 and Phase 2b/3 studies in active psoriatic arthritis (ICONIC‑PsA 1 and ICONIC‑PsA 2).
• The Phase 2b ANTHEM‑UC study in moderately to severely active ulcerative colitis, with data supporting Phase 3 development in ulcerative colitis and a Phase 2b/3 program in Crohn’s disease.

Rusfertide is described as a mimetic of the natural hormone hepcidin and a first‑in‑class investigational subcutaneous hepcidin mimetic peptide. It is designed to regulate iron homeostasis and red blood cell production, with the goal of controlling hematocrit levels in adults with polycythemia vera (PV), a rare blood disorder characterized by erythrocytosis. Protagonist and its partner Takeda report that rusfertide is being evaluated in the Phase 3 VERIFY study and related extension studies (including THRIVE), and that rusfertide has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA for PV. An NDA for rusfertide for the treatment of adults with polycythemia vera has been submitted to the FDA.

Collaboration and licensing model

Protagonist’s disclosures emphasize a collaboration-driven model for its late-stage assets. Icotrokinra is licensed to Janssen Biotech, Inc., a Johnson & Johnson company, under a license and collaboration agreement that covers discovery and development of IL‑23R‑targeted compounds. Under this collaboration, Protagonist led early-stage development and Johnson & Johnson is responsible for later-stage clinical development and commercialization rights.

For rusfertide, Protagonist has entered into a worldwide collaboration and license agreement with Takeda Pharmaceuticals. The company states that rusfertide is being co-developed and will be co-commercialized with Takeda, with Protagonist remaining primarily responsible for development through NDA filing. The agreement includes provisions for milestone payments, opt-out rights, and tiered royalties on worldwide net sales, as described in company news releases.

Pipeline beyond lead programs

In addition to icotrokinra and rusfertide, Protagonist reports several preclinical and early clinical programs derived from its peptide discovery platform. These include:

• PN‑881, described as a first‑in‑class oral IL‑17 peptide antagonist. Company announcements note preclinical proof‑of‑concept data and initiation of a Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults.
• PN‑477, referred to as an obesity triple agonist peptide, with oral (PN‑477o) and subcutaneous (PN‑477sc) formulations progressing through IND‑enabling studies.
• An oral hepcidin program, from which Protagonist plans to nominate a development candidate for IND‑enabling studies.

Across these programs, Protagonist characterizes its focus as addressing clinically and commercially validated targets with peptide-based therapeutics, particularly in inflammatory and immunological (I&I) indications and hematologic disorders.

Regulatory and clinical milestones

Company news releases highlight several regulatory milestones and clinical data readouts relevant to PTGX:

• Submission of an NDA to the U.S. FDA for icotrokinra in moderate to severe plaque psoriasis, and a corresponding application to the EMA.
• Positive Phase 3 data for icotrokinra in plaque psoriasis from ICONIC‑LEAD, ICONIC‑TOTAL, and ICONIC‑ADVANCE 1 and 2, including comparisons to placebo and to deucravacitinib.
• Phase 2b ANTHEM‑UC data in ulcerative colitis, with icotrokinra meeting the primary endpoint of clinical response at multiple doses and supporting further development in UC and Crohn’s disease.
• Phase 3 VERIFY data for rusfertide in polycythemia vera, including 32‑week and 52‑week analyses showing response rates defined by absence of phlebotomy eligibility, hematocrit control, and patient‑reported outcomes, as reported by Protagonist and Takeda.
• Long‑term extension data from THRIVE and combined REVIVE/THRIVE analyses, indicating reductions in phlebotomy rates and sustained hematocrit control in patients treated with rusfertide.

These milestones are presented by the company as part of a progression from discovery through late-stage development, with multiple programs at or approaching regulatory review.

Corporate profile and listing

Protagonist Therapeutics, Inc. is incorporated in Delaware and lists its principal executive offices in Newark, California, as disclosed in its Form 8‑K filings. The company’s common stock trades on the Nasdaq Global Market under the ticker symbol PTGX. SEC filings reference Protagonist as a biopharmaceutical company and include regular updates on financial results, corporate presentations, and stockholder meeting outcomes.

Through its SEC reports and press releases, Protagonist emphasizes its role as a clinical‑stage biopharmaceutical company advancing peptide‑based therapies from discovery into late-stage development, with a strategy that combines internal R&D with collaborations with larger pharmaceutical partners.

How investors may view PTGX

From the information Protagonist provides, PTGX represents exposure to a pipeline of peptide therapeutics targeting validated pathways such as IL‑23, IL‑17, and hepcidin. The company’s narrative focuses on:

• Late-stage assets (icotrokinra and rusfertide) with NDAs submitted or planned.
• Partnerships with Johnson & Johnson and Takeda for development and commercialization.
• Expansion of its platform into additional inflammatory, immunological, and metabolic indications via PN‑881, PN‑477, and oral hepcidin programs.

All of these elements are drawn from Protagonist’s own descriptions in press releases and SEC filings, and reflect how the company characterizes its business and pipeline to the market.